-
公开(公告)号：US20100292248A1
公开(公告)日：2010-11-18
申请号：US12843967
申请日：2010-07-27
IPC分类号： A61K31/497 , A61P25/16
CPC分类号： A61K31/137 , A61K31/198 , A61K31/496 , A61K2300/00
摘要： A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof: and L-DOPA or at least one pharmacologically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function using this composition, including Parkinson's disease and restless leg syndrome.
摘要翻译： 含有SLV308或其N-氧化物或其至少一种药学上可接受的盐的组合物：和L-DOPA或其至少一种药理学上可接受的盐，用于同时，分别或顺序地用于治疗需要恢复多巴胺能功能的疾病，其使用 这种组合物，包括帕金森病和不宁腿综合征。
-
公开(公告)号：US20070293505A1
公开(公告)日：2007-12-20
申请号：US11762206
申请日：2007-06-13
IPC分类号： A61K31/496 , A61K31/198 , A61K31/137
CPC分类号： A61K31/137 , A61K31/198 , A61K31/496 , A61K2300/00
摘要： A composition containing SLV308 or its N-oxide, or at least one pharmacologically acceptable salt thereof: and L-DOPA or at least one pharmacologically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of disorders requiring recovery of dopaminergic function using this composition, including Parkinson's disease and restless leg syndrome.
摘要翻译： 含有SLV308或其N-氧化物或其至少一种药学上可接受的盐的组合物：和L-DOPA或其至少一种药理学上可接受的盐，用于同时，分别或顺序地用于治疗需要恢复多巴胺能功能的疾病，其使用 这种组合物，包括帕金森病和不宁腿综合征。
-
公开(公告)号：US20090005395A1
公开(公告)日：2009-01-01
申请号：US12143915
申请日：2008-06-23
IPC分类号： A61K31/519 , C07D487/04 , A61P15/10 , A61P9/12
CPC分类号： C07D487/04
摘要： Embodiments of the present invention relate to a compound of formula (1A) or a pharmacologically acceptable salt, hydrate, or solvate thereof. Other embodiments of the present invention relate to a pharmaceutical composition containing this compound, to methods for preparing this compound, and to methods for preparing compositions containing this compound. Yet other embodiments of the invention relate to uses of this compound, and compositions containing it, for the manufacture of medicaments and pharmaceutical compositions for treating erectile dysfunction or pulmonary arterial hypertension.
摘要翻译： 本发明的实施方案涉及式（1A）化合物或其药理学上可接受的盐，水合物或溶剂化物。 本发明的其它实施方案涉及含有该化合物的药物组合物，该化合物的制备方法以及含有该化合物的组合物的制备方法。 本发明的其它实施方案涉及该化合物及其含有组合物用于制备用于治疗勃起功能障碍或肺动脉高压的药物和药物组合物的用途。
-
4.发明申请公开(公告)号：US20090005455A1
公开(公告)日：2009-01-01
申请号：US12143919
申请日：2008-06-23
IPC分类号： A61K31/135 , C07C217/74 , A61P25/00 , C07C215/56
CPC分类号： C07C291/04
摘要： Embodiments of the invention relate to a compound of formula (1), or a tautomer, stereoisomer, hydrate, or solvate thereof, wherein R1 is H or CH3. Other embodiments of the invention relate to a pharmaceutical composition containing these compound, to methods for preparing these compounds, and to methods for preparing compositions containing these compounds. Yet other embodiments of the invention relate to the uses of these compounds and compositions containing it, such as for the manufacture of medicaments and pharmaceutical compositions for treating a condition chosen from depression, major depressive disorder, generalized anxiety disorder, obsessive compulsive disorder, social anxiety disorder, panic disorder, general depressive disorders, diabetic neuropathy, migraine and hot flashes.
摘要翻译： 本发明的实施方案涉及式（1）的化合物或其互变异构体，立体异构体，水合物或溶剂合物，其中R 1为H或CH 3。 本发明的其它实施方案涉及含有这些化合物的药物组合物，制备这些化合物的方法以及制备含有这些化合物的组合物的方法。 本发明的其它实施方案涉及这些化合物和含有它们的组合物的用途，例如用于制备用于治疗选自抑郁症，重度抑郁障碍，广泛性焦虑症，强迫症，社会焦虑症的药物和药物组合物 障碍，恐慌症，一般抑郁障碍，糖尿病性神经病，偏头痛和潮热。
-
公开(公告)号：US20100120752A1
公开(公告)日：2010-05-13
申请号：US12690822
申请日：2010-01-20
申请人： Natasja M.W.J. De Bruin , Marlies L. Van Drimmelen , Arnoldus H.J. Herremans , Martinus Th.M. Tulp , Cornelis G. Kruse
发明人： Natasja M.W.J. De Bruin , Marlies L. Van Drimmelen , Arnoldus H.J. Herremans , Martinus Th.M. Tulp , Cornelis G. Kruse
IPC分类号： A61K31/551 , A61K31/4439 , A61K31/439 , A61P25/18 , A61P25/22 , A61P25/30 , A61P25/32
CPC分类号： A61K31/5513
摘要： The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, for example muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders ‘Not Elsewhere Classified,’ such as intermittent explosive disorder, pyromania, kleptomania, pathological gambling and trichotillomania, and impulse control disorders ‘Not Otherwise Specified,’ such as compulsive buying disorder, binge eating and binge drinking disorder, impulsive self-injurious behavior, sexual addictions, compulsive Internet use, and excessive mobile phone use.
摘要翻译： 本发明涉及毒蕈碱的化合物及其药学上可接受的盐的新用途，例如毒蕈碱-1（M1）激动剂。 这些化合物可用于制备用于治疗，改善或预防冲动控制障碍的药物。 这些包括脉冲控制障碍“非其他分类”，如间歇性爆发性疾病，原发性幽门螺杆菌，轻度恐怖症，病理性赌博和拔毛病，以及冲动控制障碍“无其他指定”，如强迫性购买障碍，暴饮暴食和暴饮暴食，冲动 自我伤害行为，性成瘾，互联网强制使用和手机使用过多。
-
公开(公告)号：US20070259859A1
公开(公告)日：2007-11-08
申请号：US11741976
申请日：2007-04-30
申请人： Natasja M.W.J. De Bruin , Marlies L. Van Drimmelen , Arnoldus H.J. Herremans , Martinus Th.M. Tulp , Cornelis G. Kruse
发明人： Natasja M.W.J. De Bruin , Marlies L. Van Drimmelen , Arnoldus H.J. Herremans , Martinus Th.M. Tulp , Cornelis G. Kruse
IPC分类号： A61K31/5513
CPC分类号： A61K31/5513
摘要： The invention relates to a novel use of compounds and pharmaceutically acceptable salts thereof, which are muscarinic, for example muscarine-1 (M1) agonists. These compounds are useful for the preparation of medicaments for treatment, amelioration or prevention of impulse control disorders. These include impulse control disorders ‘Not Elsewhere Classified,’ such as intermittent explosive disorder, pyromania, kleptomania, pathological gambling and trichotillomania, and impulse control disorders ‘Not Otherwise Specified,’ such as compulsive buying disorder, binge eating and binge drinking disorder, impulsive self-injurious behavior, sexual addictions, compulsive Internet use, and excessive mobile phone use.
摘要翻译： 本发明涉及毒蕈碱的化合物及其药学上可接受的盐的新用途，例如毒蕈碱-1（M 1 H 1）激动剂。 这些化合物可用于制备用于治疗，改善或预防冲动控制障碍的药物。 这些包括脉冲控制障碍“非其他分类”，如间歇性爆发性疾病，原发性幽门螺杆菌，轻度恐怖症，病理性赌博和拔毛病，以及冲动控制障碍“无其他指定”，如强迫性购买障碍，暴饮暴食和暴饮暴食，冲动 自我伤害行为，性成瘾，互联网强制使用和手机使用过多。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.038 秒)
